ounce
Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats
Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA
Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy
Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs
Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy
Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.
Dr. Mehmet Oz Nominated to Lead Centers for Medicare and Medicaid Services
Dr. Mehmet Oz, Medicare, Medicaid, Centers for Medicare and Medicaid Services, Trump nomination, healthcare leadership